1 -ФГБУ "НИИ вакцин и сывороток им. И.И.Мечникова" РАМН: 105064, Москва, Малый Казенный пер., 5а 2 -ФГБУ "НИИ пульмонологии" ФМБА России: 105077, Москва, ул. 11 я Парковая, 32, корп. 4 3 -ЗАО Научно производственная компания "Комбиотех": 117871, Москва, ул. Миклухо Маклая, 16/10, ИБХ РАН, корп. 71 M.P. SummaryCurrently, development of immune response to vaccines has not been studied completely; data on vaccines safety and effect on the course of chron ic obstructive pulmonary disease (COPD) are lacking. Thus, vaccination against diphteria and pertussis of patients with COPD is of great impor tance. The aim of our study was to evaluate efficacy and safety of a vaccine against diphteria and pertussis in patients with COPD. We examined 61 moderate to severe COPD patients aged 35 to 65 years. Of them, 33 patients received the Bubo M vaccine trice according to 0-1-6 month regimen and 28 patients received the same vaccine only once. Thirty four healthy subjects vaccinated with the same vaccine were as controls. The Bubo M vaccine was well tolerated; no serious post vaccine adverse events were registered. Vaccination of COPD patients did not influence the rate of acute respiratory infection episodes and did not increase the rate of acute exacerbations of COPD. A characteristic feature of immune response to the vac cine in COPD patients was slower antibody production against diphteria and pertussis anatoxins.
The article presents the results of vaccination against diphtheria, tetanus and hepatitis B virus with the use of combined vaccine Bubo-M or a monovalent vaccine Hepatitis B in 120 patients with severe and medium chronic obstructive pulmonary disease (COPD) and 77 healthy people at the age 35 - 60 years. The lack of protective antibodies to diphtheria in patients with COPD was noted. The safety of immunization and the delayed production of post-vaccination antibodies to these infections were shown. The level of post-vaccination antibodies was the same as in healthy group after the administration of 3-rd dose both of the monovaccine and the combined one. During the year a clinical effect in reducing the number of exacerbations of the disease after a triple injection of the combined Bubo-M vaccine in patients with COPD was observed, comparable to that in patients with the combined use of the immunomodulator and hepatitis B vaccine. Moreover combined vaccination with immunomodulator led to normalization of level of the inflammatory mediators. Conclusion: Vaccination of patients with COPD with the use of the combined vaccine Bubo-M has both an advantages in clinical effect and the spectrum of anti-infection protection in comparison with the monovaccine against hepatitis
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.